Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2024 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Completes Recruitment for the Synchronicity Study

ATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
January 02, 2024 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients,...
December 12, 2023 07:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients,...
November 08, 2023 16:30 ET | Source: Alimera Sciences, Inc.

Alimera Appoints Maggie A. Pax to Its Board of Directors

ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
October 31, 2023 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology

ATLANTA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
October 26, 2023 07:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Reports Third Quarter 2023 Results

Net Revenue up 72% to $23.4 Million vs. Q3 2022Net Loss Decreased by 74% to $1.4 Million vs. Q3 2022Adjusted EBITDA of $5.4 Million in Q3 2023Successful Integration of YUTIQ into the U.S. Segment ...
October 16, 2023 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate Update

ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
October 11, 2023 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress

ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
October 03, 2023 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Appoints Jason Werner as Chief Operating Officer

ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
September 05, 2023 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

ATLANTA, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right